CDK3, target of miR-4469, suppresses breast cancer metastasis via inhibiting Wnt/β-catenin pathway
Metrics: PDF 1839 views | HTML 2576 views | ?
Ting Cao1,4,*, Tian Xiao1,*, Guanqun Huang1, Yafei Xu1, Joe Jiang Zhu1, Kaixin Wang5, Wencai Ye4, Hong Guan3, Jinsong He2 and Duo Zheng1
1Department of Cell Biology and Genetics, Shenzhen University Health Science Center, Shenzhen 518060, Guangdong Province, China
2Department of Breast Surgery, The First Affiliated Hospital of Shenzhen University, Second People’s Hospital of Shenzhen, Shenzhen 518035, Guangdong Province, China
3Department of Pathology, The First Affiliated Hospital of Shenzhen University, Second People’s Hospital of Shenzhen, Shenzhen 518035, Guangdong Province, China
4Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Jinan University, Guangzhou 510632, Guangdong Province, China
5Department of Pathology, Shenzhen Nanshan People’s Hospital, Shenzhen 518052, Guangdong Province, China
*These authors contributed equally to this work
Hong Guan, email: email@example.com
Jinsong He, email: firstname.lastname@example.org
Duo Zheng, email: email@example.com
Keywords: CDK3, breast cancer, metastasis, microRNA, Wnt pathway
Received: March 06, 2017 Accepted: May 08, 2017 Published: May 25, 2017
Cyclin-dependent kinase 3 (CDK3), a member of CDK family, is involved in G0/G1 and G1/S cell cycle transitions. Although several researchers discovered that CDK3 related to cell growth in some kinds of cancer, the functions of CDK3 during tumor development remains unclear. Here, we first found that the expression of CDK3 was higher in primary tumors of non-metastatic breast cancer compared with those in metastatic breast cancer. Overexpression of CDK3 suppressed cell migration and invasion of breast cancer cells, and decreased the metastasis in nude mice. We further identified miR-4469 was a negative regulator of CDK3 by directly targeting its 3′-untranslated region (UTR). The increase of motility induced by miR-4469 could be abolished by CDK3 overexpression. Moreover, RNA-seq analysis revealed that Wnt pathway may be inhibited by CDK3 expression, which was subsequently confirmed by western blot. Moreover, Wnt3a treatment abolished the inhibitory role of CDK3 in cell motility, suggesting that Wnt signaling is the potential downstream of CDK3. In conclusion, these results support that CDK3 which is targeted by miR-4469 suppresses breast cancer metastasis by inhibiting Wnt/β-catenin pathway.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.